Compare SCNI & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCNI | ACON |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.4M |
| IPO Year | N/A | 2022 |
| Metric | SCNI | ACON |
|---|---|---|
| Price | $0.71 | $5.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 59.7K | ★ 111.3K |
| Earning Date | 03-27-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,147,000.00 | $67,483.00 |
| Revenue This Year | N/A | $71.77 |
| Revenue Next Year | N/A | $80.52 |
| P/E Ratio | $2.67 | ★ N/A |
| Revenue Growth | ★ 303.87 | 36.91 |
| 52 Week Low | $0.70 | $5.02 |
| 52 Week High | $6.18 | $3,499.49 |
| Indicator | SCNI | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 29.41 | 35.55 |
| Support Level | $0.70 | $5.02 |
| Resistance Level | $0.80 | $6.40 |
| Average True Range (ATR) | 0.09 | 0.49 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 3.08 | 7.56 |
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.